Skip to content
Study details
Enrolling now

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

St. Jude Children's Research Hospital
NCT IDNCT06810583ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

29

Study length

about 5.4 years

Ages

≤25

Locations

1 site in TN

What this study is about

This trial is testing dalbavancin, a medication, as a preventative measure against bacterial infections in children and adolescents with leukemia who are receiving chemotherapy. The goal is to see how effective this treatment is at preventing bloodstream infections and other complications.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Dalbavancin
  • 2.Take Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

dalbavancin, antibiotic (Fluoroquinolone antibiotic; inhibits bacterial DNA gyrase)

Drug routes

injection, intravenous, oral (Oral Tablet)

Endpoints

Secondary: Dalbavancin peak plasma concentration (Cmax) - Median and range, Tolerability of dalbavancin

Body systems

Oncology